Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932113 · ClinicalTrials.gov registry record · Phase 4
Mechanism of Action Study for Psoriasis
A Phase 4 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT00932113 is a Phase 4 study that has completed, run by Tufts Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT00932113, a Phase 4 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
The objective of this study is to compare the mechanism of action between adalimumab and methotrexate in subjects with psoriasis.
Interventions
- DRUG Methotrexate
- DRUG Adalimumab (Humira)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-06 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932113
The ClinicalTrials.gov registry entry for NCT00932113 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT00932113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932113 about?
NCT00932113 is a clinical study titled "Mechanism of Action Study for Psoriasis". The objective of this study is to compare the mechanism of action between adalimumab and methotrexate in subjects with psoriasis.
What is the current status of trial NCT00932113?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2009-06. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT00932113?
The interventions under investigation include: Methotrexate (DRUG), Adalimumab (Humira) (DRUG).
Who is sponsoring clinical trial NCT00932113?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.